ArticleBMC infectious diseases2025
Investigation of potential relationship betweenmazEF3, relJK, and vapBC3 genes and antimicrobial resistance inMycobacterium bovis.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative in silico analysis of vapBC3 toxin-antitoxin system in Mycobacterium Bovis and Mycobacterium tuberculosis.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSmall genetic modules, such as toxin-antitoxin (TA) systems, play specific roles in persistence, antibiotic resistance, and virulence in pathogenic bacteria. Given the transmission of M. bovis to humans and the importance of the spread of antibiotic resistance in this bacterium, this study aimed to compare the presence and sequences of the mazEF3, vapBC3, and relJK genes in type II TA systems of both resistant and sensitive M. bovis isolates.
methodsFifty-nine M. bovis isolates were obtained from the Razi Vaccine and Serum Research Institute in Iran. M. bovis isolates were confirmed using GeneXpert MTB/RIF and by evaluating of the pncA gene. Rifampin- and isoniazid-resistant isolates were identified using Multiplex Allele-Specific Polymerase Chain Reaction (MAS-PCR). The presence and mutations of the mazEF3, relJK, and vapBC3 genes were analyzed by PCR sequencing. Molecular docking was performed to predict the binding affinity of RelJ to RelK.
resultsOf the 59 M. bovis isolates, 13 (22%) and 3 (5.1%) were resistant to rifampin and isoniazid, respectively. The most common mutations in the rifampin-resistant isolates were observed at codons rpoB516 (92.3%) and rpoB531 (84.6%). The nucleotide sequences of mazEF3, vapBC3, and relK were identical to those in the reference strain in all cases. Molecular docking analysis suggests that the mutant RelJ shows improved binding affinity in comparison to the non-mutant protein for the RelK toxin.
conclusionsThese findings suggest that the relJ gene may be associated with antibiotic resistance in M. bovis. Therefore, increasing the sample size is recommended for a more in-depth investigation of relJ. If successful, this biomarker could be utilized for developing new methods to identify resistant isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.